Updating results

153 results

Sort: Relevance | Date

Hyperhidrosis: oxybutynin (ES10)

Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published March 2017

Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab (ES1)

Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making

Evidence summary Published November 2016

Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

Evidence summary Published March 2017

Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

Summary of the evidence on bezlotoxumab for preventing the recurrence of Clostridium difficile (C difficile) infection

Evidence summary Published June 2017

Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

Summary of the evidence on liraglutide for managing obesity and overweight with risk factors in adults to inform local NHS planning and decision-making

Evidence summary Published June 2017

Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

ES12 Key points The content of this evidence summary

Evidence summary Published April 2017

Type 1 diabetes: insulin degludec (ESNM24)

Summary of the evidence on insulin degludec for treating type 1 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Type 2 diabetes: insulin degludec (ESNM25)

Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Type 2 diabetes: lixisenatide (ESNM26)

Summary of the evidence on lixisenatide (glucagon-like peptide-1 [GLP-1] mimetic) for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Combined oral contraception: nomegestrol/estradiol (Zoely) (ESNM28)

Summary of the evidence on nomegestrol/estradiol (Zoely) for use as combined oral contraception to inform local NHS planning and decision-making

Evidence summary Published December 2013

Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

Summary of the evidence on the indacaterol/glycopyrronium (Ultibro Breezhaler) for relieving the symptoms of chronic obstructive pulmonary disease (COPD)..

Evidence summary Published February 2014 Last updated March 2014

Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

Summary of the evidence on the fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler for asthma to inform local NHS planning and decision-making

Evidence summary Published March 2014

Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)

Summary of the evidence on canakinumab for treating systemic juvenile idiopathic arthritis (JIA) to inform local NHS planning and decision-making

Evidence summary Published March 2014

Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

Summary of the evidence on zonisamide as adjunctive therapy for partial seizures in children and young people (aged 6–17 years) with epilepsy..

Evidence summary Published March 2014

Induction of labour: misoprostol vaginal delivery system (ESNM38)

Summary of the evidence on the misoprostol vaginal delivery system for induction of labour to inform local NHS planning and decision-making

Evidence summary Published March 2014 Last updated November 2014

Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

Evidence summary Published September 2014

Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)

Summary of the evidence on beclometasone/formoterol (Fostair) for treating chronic obstructive pulmonary disease (COPD)...

Evidence summary Published September 2014

Facial erythema of rosacea: brimonidine tartrate gel (ESNM43)

Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making

Evidence summary Published July 2014

Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

Summary of the evidence on telavancin (Vibativ) for hospital-acquired pneumonia caused by MRSA to inform local NHS planning and decision-making

Evidence summary Published July 2014

Erectile dysfunction: avanafil (ESNM45)

Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

Evidence summary Published August 2014

Schizophrenia: lurasidone (ESNM48)

Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

Evidence summary Published September 2014

Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)

Summary of the evidence on umeclidinium/vilanterol combination inhaler (Anoro Ellipta) for treating chronic obstructive pulmonary disease (COPD)...

Evidence summary Published November 2014

Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

Summary of the evidence on aripiprazole prolonged-release suspension for injection for schizophrenia to inform local NHS planning and decision-making

Evidence summary Published March 2014

Premature ejaculation: dapoxetine (ESNM40)

Summary of the evidence on dapoxetine for premature ejaculation to inform local NHS planning and decision-making

Evidence summary Published May 2014

Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)

Summary of the evidence on the levonorgestrel intrauterine delivery system (long-acting reversible contraception) to inform local NHS planning...

Evidence summary Published June 2014

Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)

Summary of the evidence on fluticasone/formoterol (Flutiform) combination inhaler for treating asthma to inform local NHS planning and decision-making

Evidence summary Published October 2012

Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

Summary of the evidence on triptorelin (Decapeptyl SR) for treating prostate cancer to inform local NHS planning and decision-making

Evidence summary Published January 2014

Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)

Summary of the evidence on beclometasone/formoterol (Fostair) for treating asthma to inform local NHS planning and decision-making

Evidence summary Published June 2013

Gouty arthritis: canakinumab (ESNM23)

Summary of the evidence on canakinumab for treating gouty arthritis (gout) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Interstitial cystitis: dimethyl sulfoxide bladder instillation (ESUOM26)

Summary of the evidence on dimethyl sulfoxide bladder instillation for treating interstitial cystitis to inform local NHS planning and decision-making

Evidence summary Published February 2014

Chronic pain: oral ketamine (ESUOM27)

Summary of the evidence on oral ketamine for treating chronic pain to inform local NHS planning and decision-making

Evidence summary Published February 2014 Last updated June 2014

Difficult-to-treat scabies: oral ivermectin (ESUOM29)

Summary of the evidence on oral ivermectin for treating difficult-to-treat scabies to inform local NHS planning and decision-making

Evidence summary Published March 2014

Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published January 2013

Pouchitis: rifaximin (ESUOM30)

Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

Evidence summary Published March 2014

Chronic urticaria: off-label doses of cetirizine (ESUOM31)

Summary of the evidence on off-label doses of cetirizine for chronic urticaria (hives) to inform local NHS planning and decision-making

Evidence summary Published July 2014

Scleroderma: oral mycophenolate (ESUOM32)

Summary of the evidence on oral mycophenolate for systemic sclerosis (scleroderma) to inform local NHS planning and decision-making

Evidence summary Published July 2014

Pulmonary hypertension in neonates: sildenafil (ESUOM51)

Summary of the evidence on sildenafil for treating pulmonary hypertension in neonates to inform local NHS planning and decision-making

Evidence summary Published March 2016

Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)

Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making

Evidence summary Published February 2013

Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)

Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published March 2013

Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

Summary of the evidences on clonidine for attention deficit hyperactivity disorder (ADHD) in children and young people..

Evidence summary Published April 2013

Fatigue in multiple sclerosis: modafinil (ESUOM9)

Summary of the evidence on modafinil for treating fatigue in multiple sclerosis (MS) to inform local NHS planning and decision-making

Evidence summary Published April 2013

Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

Evidence summary Published June 2015

Symptoms of peripheral arterial disease: ramipril (ESUOM45)

Summary of the evidence on ramipril for relieving the symptoms of peripheral arterial disease (PAD) to inform local NHS planning and decision-making

Evidence summary Published June 2015

Hypersexuality: fluoxetine (ESUOM46)

Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making

Evidence summary Published July 2015

Infantile haemangioma: topical timolol (ESUOM47)

Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making

Evidence summary Published August 2015

Migraine prophylaxis: flunarizine (ESUOM33)

Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making

Evidence summary Published September 2014

Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)

Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis...

Evidence summary Published October 2014

Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

Evidence summary Published October 2014

Systemic lupus erythematosus: oral mycophenolate (ESUOM36)

Summary of the evidence on oral mycophenolate for systemic lupus erythematosus (SLE) to inform local NHS planning and decision-making

Evidence summary Published November 2014

Autoimmune haemolytic anaemia: rituximab (ESUOM39)

Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

Evidence summary Published February 2015